SCHEMBL239828

SCHEMBL239828

Cc1nc2cc(C3CC3)nn2c(N)c1CO

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.37
RAB9A P51151 5/20 0.37
PIK3CG P48736 1/20 0.35
ALDH1A1 P00352 8/20 0.33
HPGD P15428 6/20 0.33
SMN1; SMN2 Q16637 5/20 0.33
NFKB1 P19838 1/20 0.33
HTT P42858 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
KDM4E B2RXH2 6/20 0.32
MAPT P10636 4/20 0.31
LMNA P02545 4/20 0.31
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
TP53 P04637 2/20 0.31
CYP2C19 P33261 1/20 0.31
NPSR1 Q6W5P4 3/20 0.31
PKM P14618 2/20 0.31
CDK5 Q00535 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL238864 0.81 KDM4E (0.47) NPC1RAB9APIK3CGALDH1A1HPGD
SCHEMBL239374 0.76 NPC1 (0.37) NPC1RAB9APIK3CGALDH1A1HPGD
SCHEMBL237634 0.76 NPC1 (0.37) NPC1RAB9APIK3CGALDH1A1HPGD
SCHEMBL238224 0.75 PLAT (0.43) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL239025 0.72 FYN (0.38) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL5052666 0.71 MAPT (0.42) NPC1RAB9APIK3CGALDH1A1HPGD
SCHEMBL238498 0.68 KDR (0.40) PDE10A
SCHEMBL5056012 0.68 RAB9A (0.44) NPC1RAB9APIK3CGALDH1A1HPGD
SCHEMBL235071 0.68 NPC1 (0.36) NPC1RAB9AALDH1A1HPGDSMN1; SMN2
SCHEMBL21984253 0.67 HPGD (0.36) ALDH1A1HPGDSMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
EP-2406250-B1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME (US) 2015-08-12 EP disclosed
US-8614221-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2013-12-24 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY MERCK SHARP & DOHME LLC 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004240-A1 INHIBITORS OF AKT ACTIVITY PIK3CD, PIK3CA, PIK3R5 NPC1 1127/4885RAB9A 778/4885PIK3CG 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.